ERYTech Pharma SA Sponsored ADR

ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.

ERYTECH Announces $ 30.0 Million Registered Direct Offering

ERYTECH Announces $30.0 Million Registered Direct Offering

ERYTECH Reports Cash Balance at End of Q1 202 1 and Announces the Details of its 2021 Q1 conference call

ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL

ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer

ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q4 2020 Results - Earnings Call Transcript

ERYTECH Pharma S.A. (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon

ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?

ERYTECH to Present at the 2021 BIO CEO & Investor Conference

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

ERYTECH Pharma (ERYP) Catches Eye: Stock Jumps 7.4%

Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that CEO, Gil Beyen, will present at the H.C. Wainwright Virtual BioConnect 2021 in a pre-recorded corporate overview presentation.

ERYTECH to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the completion of enrollment in the TRYbeCA-1 Phase 3 trial in second-line pancreatic cancer.

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announce d today that CEO, Gil Beyen, will present at t he JMP Securities Hematology Summit Tuesday December 15 th at 1: 3 0pm EST /0 6 : 3 0pm GMT / 7 : 3 0pm CET . The format will be a “fireside chat” discussion hosted by  JMP Securities' Reni Benjamin.

ERYTECH to Present at the JMP Securities Hematology Summit

LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2020

W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET

ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting

Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET

ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting

LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12 :00 pm EST / 05:00pm GMT / 6 :00 pm CET on November 18, 2020.

ERYTECH to Present at Jefferies Virtual Healthcare Conference

ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q3 2020 Results - Earnings Call Transcript

Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET

ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020

LYON, France and CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces that an abstract detailing results from the NOPHO spons o red Phase 2 trial of eryaspase in ALL patients, has been selected for oral presentation at the upcoming 62 nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8. A second abstract detailing population pharmacokinetics of eryaspase in ALL or pancreatic adenocarcinoma patients has been accepted for a poster presentation at the meeting.

ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual Meeting

Article 223-16 of general regulation of French Autorité des Marchés Financiers

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2020.

LYON, France and CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that it has received financing approval s from Bpifrance and Société Générale for a total of € 10 million in the form of S tate- G uaranteed L oan s ( Prêt s Garanti s par l'Etat , or PGE in France) in the context of the COVID-19 pandemic.

ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government

LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , t oday announced that it will host a Third Quarter 20 20 conference call  and webcast on Friday, November 6 , 20 20 , at 2:30 PM CET/8:30 AM EST to discuss operational highlights.

News for ERYTech Pharma SA Sponsored ADR Stock (ERYP)